Sign in

    Naz Rahman • Maxim Group

    Naz Rahman is a Vice President and biopharmaceuticals equity research analyst at Maxim Group, focusing primarily on the healthcare and biotech sectors with coverage of companies such as NexGel Inc and Processa Pharmaceuticals. Rahman has maintained a consistent track record with a reported success rate of approximately 29%, and an average return on recommendations of -17.8%, according to recent performance metrics. His career includes previous senior research roles at firms such as JMP Securities before joining Maxim Group, where he has built expertise in analyzing complex healthcare markets and stock valuations. He is registered with FINRA and holds relevant securities licenses, reflecting his compliance with industry standards for professional equity analysts.

    Naz Rahman's questions to Talphera Inc (TLPH) leadership

    Naz Rahman's questions to Talphera Inc (TLPH) leadership • Q2 2025

    Question

    Naz Rahman from Maxim Group asked for the basis of the company's confidence in activating new clinical sites on schedule and whether the recent enrollment acceleration was driven by better site selection or by drug shortages.

    Answer

    Chief Medical Officer Dr. Shakil Aslam stated that confidence in site activation comes from vetting new sites on their historical timelines and improving internal processes. CEO Vincent Angotti added that several new sites are already in the final stages of activation. Both executives clarified that the enrollment acceleration is a direct result of shifting to a new site profile with nephrologist PIs in medical ICUs, who are more engaged with CRRT. Dr. Aslam asserted that the spike is due to PI enthusiasm and the right patient population, not the ongoing drug shortages.

    Ask Fintool Equity Research AI

    Naz Rahman's questions to Nexgel Inc (NXGL) leadership

    Naz Rahman's questions to Nexgel Inc (NXGL) leadership • Q2 2025

    Question

    Naz Rahman of Maxim Group inquired about the market opportunities for upcoming STATA partnership launches, the company's retail strategy, manufacturing capacity, the economic potential of the iRhythm partnership, and the impact of tariffs.

    Answer

    CEO Adam Levy explained that new enzyme products with STATA target larger markets than HistoSolve, aiding a future retail strategy. He confirmed manufacturing capacity is still low (high teens utilization), offering significant room for growth. Levy positioned the iRhythm partnership in the $300k-$800k annual revenue range and noted that tariffs have a mild negative impact on some product margins but positively stimulate domestic interest in their hydrogels.

    Ask Fintool Equity Research AI

    Naz Rahman's questions to Assertio Holdings Inc (ASRT) leadership

    Naz Rahman's questions to Assertio Holdings Inc (ASRT) leadership • Q2 2025

    Question

    Naz Rahman of Maxim Group questioned the current and expected impact of same-day dosing data on ROLVOIDON sales, the timeline for NCCN guideline inclusion, the potential peak sales for SYMPAZAN, and whether resources from OTREXUP could be redirected to accelerate growth in core products.

    Answer

    CEO Brendan O’Grady stated that interest in ROLVOIDON's same-day dosing is increasing and expects a peer-reviewed publication this year to be a further catalyst, with potential NCCN guideline inclusion by 2026. He projected that SYMPAZAN net sales could potentially double to the $25-30 million range in the coming years. O'Grady confirmed that resources are indeed being redirected to ROLVOIDON and SYMPAZAN, but this strategic shift was already factored into the company's existing financial projections.

    Ask Fintool Equity Research AI

    Naz Rahman's questions to scPharmaceuticals Inc (SCPH) leadership

    Naz Rahman's questions to scPharmaceuticals Inc (SCPH) leadership • Q2 2025

    Question

    Naz Rahman asked for clarification on the proposed Ambulatory Specialty Model (ASM), specifically regarding the timelines for physician evaluation and the implementation process, including whether it requires congressional approval.

    Answer

    CEO John Tucker explained that the ASM rule is currently under review, with an anticipated rollout in January 2027 for data collection that will affect 2028 payments. He confirmed that CMS has the authority to implement the program without a vote from Congress. Tucker outlined the timeline, with the public comment period closing in September 2025 and physicians being notified in mid-2026, expressing strong optimism about its alignment with Furosex's value proposition.

    Ask Fintool Equity Research AI